Consort Partners

Nucleai was ranked No. 4 among top private #spatialbiology companies by Genetic Engineering & Biotechnology News thanks to its fundraising led by M Ventures and its deal with Proscia to integrate Nucleai’s predictive biomarker solutions into Proscia’s Concentriq software platform. Check out the full list here for more ⬇ : https://lnkd.in/gNMTn6_M

The TIME Best Inventions list for 2024 is out, and we're thrilled to see Spiritus recognized for its amazing Carbon Orchard! The Spiritus team has created a cleaner, more cost-efficient way to remove carbon dioxide from the air, and it's great to see their work among all the amazing inventions on this list. Read up on the Carbon Orchard here: https://lnkd.in/eYxZwJFc #TIMEBestInventions

Sherlock Biosciences is pleased to partner with BARDA on developing next generation, highly accurate, affordable tests for respiratory illnesses

When its 53,000-sq. ft. facility in Mesa, Arizona and a similar one near Philadelphia are complete, Nucleus RadioPharma will double its production capacity for #radiopharmaceuticals and be able to better serve the patients in the largest population centers in the U.S. Amy Edelen of Phoenix Business Journal looks at how Nucleus' nationwide expansion will help "improve patient access to these life-saving treatments and expedite clinical trials" while also adding jobs to two local economies. https://lnkd.in/efR6CaWj

As part of its expansion that also includes a new facility in Arizona, Nucleus RadioPharma is building a research, development and commercial production site at the Spring House Innovation Park in Lower Gwynedd, Pennsylvania. Along with ensuring life-saving radiopharmaceuticals are closer to the patients who need them, Nucleus is bringing dozens of jobs to the region, as John George explored for Philadelphia Business Journal. https://lnkd.in/e5rVagTR

By adding more than 100,000 sq. ft. of research, development and commercial production capabilities at two new sites in Mesa, Arizona, and Springhouse, Pennsylvania, Nucleus RadioPharma will be as well-positioned as anyone to ensure patients everywhere have access to life-saving radiopharmaceuticals. Kevin Dunleavy of Fierce Pharma has more on what this expansion news means for Nucleus, partners like Fox Chase Cancer Center and Mayo Clinic, and the industry as a whole. https://lnkd.in/eF57hQjT

Radiopharmaceuticals are one of the most promising areas for new treatments for cancers and other diseases, but they ideally need to be produced close to where the patients who receive them are located. Nucleus RadioPharma is taking a big step toward making that happen by announcing two new facilities. Located in Mesa, Arizona and just north of Philadelphia, these locations will help serve patients on both coasts and around the world. Anna Brown of Endpoints News has more. https://lnkd.in/dd4rVxWY

Rune Labs is excited to share that we won the The Digital Health Hub Foundation - Digital Health Awards for the Home Health Diagnostic Rising Star category for the second year in a row at HLTH Inc. Here at Rune Labs, we are transforming care for people with Parkinson’s through our StrivePD platform, which leverages AI and continuous data to provide personalized insights. By collaborating with health systems like Kaiser Permanente, we empower PwPD to stay engaged in their care between clinical visits, optimizing outcomes and reducing hospitalizations. This award is a testament to our mission to deliver data-driven, patient-centered care. Pictured below is CEO and Founder, Brian Pepin, accepting the award. Congratulations to all the other finalists and winners! #HLTH #digitalhealthawards #StrivePD #parkinsons #valuebasedcare

Our mission is to improve access to life-saving theranostic #radiopharmaceuticals for the millions of patients who need them. To that end, we’re proud to announce one of the biggest steps we’ve taken to date: the development of two new facilities in Mesa, Arizona and Springhouse, Pennsylvania. Totaling more than 100,000 square feet, these new spaces for research, development, and commercial production were chosen for their proximity to important markets. They will help contribute to local economic growth in both areas and will allow partners like Fox Chase Cancer Center and Mayo Clinic to share in the benefits of scale and location. Check out all the details at the link below: https://hubs.ly/Q02Vbny30 #NuclearMedicine #CDMO #RLT

With 300,000 new breast cancer diagnoses expected this year alone, the need to arm clinicians with new and better tools for early detection remains a crucial one. Spatial AI is emerging as a powerful addition to their toolboxes. Oscar Puig, Ph.D. of Nucleai explains how it can "can dig deeper beyond binary detection" in this fascinating piece in Drug Discovery & Development. https://lnkd.in/ezEhYCCU #breastcancer #cancerdetection #spatialai